October 8 news, East China Pharmaceutical (000963) UK wholly-owned subsidiary sinclair pharma limited (hereinafter referred to as "sinclair") obtained Belgian kiomed pharma sa (hereinafter referred to as "kiomed") 4 global innovative kimomedine under development? Chitosan aesthetic products and all subsequent development of chitosan-related products are exclusively licensed in the field of skin aesthetics in other regions of the world except the United States, including the use of kiomed related intellectual property rights for research and development, production and commercialization. Sinclair will pay Kiomed a down payment of €4 million, as well as a maximum of €10 million in R&D registration milestone payments, and an agreed percentage of net sales commission.
According to reports, kiomed 4 global innovative kiomedine in research? Chitosan aesthetic products, including 1 skin booster product and 3 filler products.
Among them, the core ingredient of skin kinesin products is kiomedine? , mainly through superficial skin injection, protect the skin from oxidative stress reactions, can effectively replenish skin moisture, improve skin texture. The product is undergoing clinical trials and is expected to receive EU CE certification in 2023.
3 filler products developed for kimed basedine? and hyaluronic acid injectable fillers that can be applied to lip filler shaping, improving or correcting facial wrinkles and skin depressions, face filler sculpting, etc. kiomedine？ The filler family of products is currently undergoing preclinical studies and is expected to be certified by the EUROPEAN Union after 2024
Founded in 2012, kiomed is a world-leading enterprise engaged in the research and development, production and sales of natural (non-animal source) chitosan, with patented technology and innovative technology platform for ultra-pure natural (non-animal source) chitosan derivatives, and its product pipeline covers orthopedics, ophthalmology, medical aesthetics and other fields.
Kiomed is the only company in the world capable of producing high-purity natural (non-animal source) medical grade chitosan extracted from edible mushrooms at CGMP level in an ISO13485 certified facility. KiomedineVs one, a chitosan injection product developed by Kiomed to relieve the pain of persistent osteoarthritis, has been CERTIFIed in the European Union.
kiomed in high purity natural (non-animal source) chitosan derivatives (kiomedine?) There is an experienced and innovative multidisciplinary team in the development of innovative chitosan-based medical aesthetic products, among which Dr. Laurence hermitte, one of the leaders of the medical aesthetic product development team, has more than 15 years of experience in polymer functionalization and medical device development in the fields of ophthalmology, rheumatology, dermatology and medical imaging, and is one of the former R&D leaders of the Swiss medical aesthetic company anteis. Anteis focuses on the research and development of hyaluronic acid products, including ophthalmology, orthopedics and cosmetic dermatology, and in 2013 anteis was acquired by merz pharma, a leading global medical aesthetic company.
This article originated from the digging shell network
![Sci Rep | improves the thermal stability of Bacillus TS chitosanase by structural alignment orientation[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)